What is Lunaphore Technologies?
Lunaphore Technologies, a Swiss-based company founded in 2014, is at the forefront of innovation in in-situ tissue analytics. The company's vision is to bring omics-like approaches to cancer research and diagnostics, aiming to revolutionize how tissue samples are analyzed. Their advanced technology focuses on enabling more precise and comprehensive insights from tissue, which is critical for both research and clinical applications. The company's commitment to advancing diagnostic capabilities positions it as a key player in the biotech and healthcare technology sectors.
How much funding has Lunaphore Technologies raised?
Lunaphore Technologies has raised a total of $92.9M across 7 funding rounds:
Series A
$2.1M
Private Equity
$6.1M
Series B
$5.3M
Series C
$23.6M
Other Financing Round
$2.1M
Debt
$10M
Series D
$43.7M
Series A (2015): $2.1M with participation from Redalpine Venture Partners
Private Equity (2017): $6.1M led by Redalpine Venture Partners, Polytech Ecosystem Ventures, Occident, and Zu00fchlke Ventures
Series B (2018): $5.3M supported by Occident and Zürcher Kantonalbank
Series C (2020): $23.6M featuring OCCIDENT, Redalpine Venture Partners, Alpana Ventures, and PHC Holdings Corporation
Other Financing Round (2020): $2.1M backed by Swiss Entrepreneurs Fund
Debt (2022): $10M with participation from Norgine Ventures Management
Series D (2023): $43.7M led by PHC Group, Redalpine, and Ernst Göhner
Key Investors in Lunaphore Technologies
PHC Group
PHC Group is a global healthcare company specializing in diagnostic services and healthcare solutions, providing medical diagnostic products and technologies worldwide. Their involvement suggests a strategic alignment with Lunaphore's mission in advancing diagnostic capabilities.
Redalpine Venture Partners
redalpine is a thesis-driven venture capital firm with expertise in software and science, focusing on empowering game changers and disrupting industries. Their investment in Lunaphore highlights a belief in the company's innovative approach to tissue analytics.
Occident
OCCIDENT is an international venture capital investor focused on innovative deep tech start-ups in life sciences and digital technologies. Their backing of Lunaphore indicates confidence in the company's technological advancements and market potential.
What's next for Lunaphore Technologies?
With the recent influx of capital, Lunaphore Technologies is poised for significant expansion and further development of its groundbreaking tissue analysis platforms. The company's strategic financing, particularly the major enterprise-level investment, suggests a focus on scaling operations, enhancing research and development efforts, and potentially broadening its market reach. This backing will likely accelerate the commercialization of their omics-like approaches, aiming to solidify their position in the competitive landscape of cancer diagnostics and research tools. Future growth may involve strategic partnerships and continued innovation in high-throughput tissue analysis.
See full Lunaphore Technologies company page
